Long-acting injectable antipsychotics for prevention and management of violent behaviour in psychotic patients

Mohr, Pavel; Knytl, Pavel; Voráčková, Veronika; Bravermanová, Anna; Melicher, Tomáš

doi:10.1111/ijcp.12997

Cited by 34 publications

(28 citation statements)

References 44 publications

Supporting

Mentioning

Contrasting

Order By: Relevance

“…We believe, however, that the updated guidelines have missed the important opportunity to face with, and to provide useful information on, the emerging issue of long-acting injectable (LAI) formulations of atypical antipsychotics. The role of LAI formulations -which have been developed as alternative to oral regimens, to sustain the release of the drug over a period of weeks, increasing the dosing interval time and improving patient adherence -is indeed growing [2][3][4][5].…”

Section: Dear Editormentioning

confidence: 99%

Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics?

2017

View full text Add to dashboard Cite

The updated AGNP Consensus Guidelines for Therapeutic Drug Monitoring (TDM) in Neuropsychopharmacology recently published in the journal have reinforced the key role of TDM to individualize psychoparmacological therapies in clinical practice. However, we believe, that these guidelines have missed the important opportunity to face with, and to provide useful information on, the emerging issue of long-acting injectable formulations of atypical antipsychotics. Specific therapeutic ranges also for these formulations should be included in the next AGNP guidelines.

show abstract

Section: Dear Editormentioning

confidence: 99%

Can We Rely on AGNP Therapeutic Targets Also For LAI Antipsychotics?

2017

View full text Add to dashboard Cite

show abstract

“…36 Additionally, it is worth noting that LAI antipsychotics have been associated with decreased rates of violence and criminality when compared with their oral counterparts. 37 In fact, the benefits of LAI antipsychotics are such that they produce an approximately 30% reduction in mortality risk when compared with the same antipsychotics prescribed in oral formulations in schizophrenia-spectrum disordered patients. 38 Unfortunately, LAI antipsychotics are infrequently used and thus are less familiar.…”

Section: Antipsychotic Trialsmentioning

confidence: 99%

Dopamine antagonist antipsychotics in diverted forensic populations

2019

View full text Add to dashboard Cite

In community settings, negative symptoms and cognitive deficits are the primary barriers to independent living, stable relationships, and employment for individuals suffering from schizophrenia-spectrum disorders. In contrast, however, positive psychotic symptoms (e.g., command hallucinations and persecutory delusions) often drive behavior which serves as the gateway to arrest and criminalization. Historically, the keystone of treatment for positive psychotic symptoms has been antagonism of dopamine D2 receptors in the mesolimbic tract. In this article, we review and explore the principles underlying dopamine antagonism for the treatment of psychosis; optimization of dopamine antagonists in treating positive psychotic symptoms; the advantages of depot dopamine antagonist antipsychotics in forensic settings; the concepts of pharmacokinetic and pharmacodynamic treatment failures; and the role of medication plasma concentrations in optimizing and managing treatment.

show abstract

“…As a bibliometric experiment, I made a list of all EC articles from 2016 to 2017, excluding editorials, and examined the number of downloads from the journal's website ascertained by Wiley as of 22 August 2018 (Table ). For the articles published in 2016 and 2017, I also compiled a list of the top 10 downloaded articles from the journal (Table ).…”

Section: Articles From the International Journal Of Clinical Practicementioning

confidence: 99%